Cargando…
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.
Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclita...
Autores principales: | Chao, Y., Chan, W. K., Birkhofer, M. J., Hu, O. Y., Wang, S. S., Huang, Y. S., Liu, M., Whang-Peng, J., Chi, K. H., Lui, W. Y., Lee, S. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062942/ https://www.ncbi.nlm.nih.gov/pubmed/9662247 |
Ejemplares similares
-
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2006) -
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012) -
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
por: Guan, Z, et al.
Publicado: (2003) -
A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated
por: Chen, Y-M, et al.
Publicado: (2004) -
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
por: Hamaguchi, T, et al.
Publicado: (2007)